12:00 AM
Apr 17, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Memantine: Phase III

NTII partner Merz + Co. GmbH & Co. (Frankfurt, Germany) said that Memantine significantly improved cognitive performance compared to placebo in two European Phase III trials in a total of 900 patients with mild...

Read the full 149 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >